Date Funded: 12/15

The DBAF and DBA Canada proudly increased awareness among attendees at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition held in Orlando, FL.

Date Funded: 12/15

The DBAF and DBA Canada provided a $56,225 grant to Colin Sieff’s, MB, BCh, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston Children’s Hospital, Boston, MA research project entitled, “Developmental erythropoiesis in a new murine model of Diamond Blackfan anemia.” The application describes a novel and potentially informative mouse model of DBA. The field has long awaited such a mouse as previous attempts to generate DBA mouse models have been disappointing in one way or another.

Date Funded: 4/15

The DBAF and DBA Canada awarded a grant to Johan Flygare, M.D., Ph.D. at Lund University in Sweden for his project entitled, “A novel group of kinase inhibitors for treatment of Diamond Blackfan Anemia.” Preliminary research has identified 12 potential drug targets compounds that rescue production of red blood cells in our RPS19-deficient mouse model for DBA. Dr. Flygare’s project will continue drug development using a completely novel strategy for treating DBA.

Date Funded: 2/15

The DBAF awarded a grant to Dr. Steve Ellis, Ph.D. at the University of Louisville to continue to provide experimental services to clinicians and scientists worldwide in need of his laboratory’s expertise in studying different aspects of ribosome synthesis relevant to DBA. Not only is Steve the dedicated (and unpaid) DBAF Research Director, he also writes the DBAF’s e-newsletter monthly Journal Club and his laboratory provides valuable research support services to the wider DBA Community.

Date Funded: 1/15

The DBAF, in collaboration with DBA-UK, awarded Nicholas James Watkins, Ph.D. at the University of Newcastle upon Tyne in the United Kingdom a grant for a project entitled, “Ribosome biogenesis, cellular signaling pathways and Diamond Blackfan anemia.” Dr. Watkins’ laboratory has recently identified two regulators of the 5S RNP signaling complex that could represent potential targets for the development of new drugs to treat DBA.

Date Funded: 1/15

The DBAF supported the 2015 Ribosome Synthesis Meeting held tri-annually with a donation. The meeting focuses on the mechanisms of ribosome assembly in eukaryotes and prokaryotes, the molecular basis for ribosomopathies, and the role of specialized ribosomes.